NetraMark, a wholly owned subsidiary of Nurosene, is providing next-generation AI solutions for pharmaceutical and biotechnology companies.
Increase efficiency, reduce costs and failure rate.
The NetraMark technology helps to de-risk clinical trials by ingesting clinical trial data and creating patient stratification datasets to inform enrichment criteria for future phases.
Meet the Team
We’re a team of mathematicians, scientists, doctors, and pharma experts.